Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 5/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | APP | P05067 | 1/20 | 0.36 |
| ▸ | SNCA | P37840 | 1/20 | 0.36 |
| ▸ | SLC16A1 | P53985 | 2/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2090193 | 1.00 | PTGDR2 (0.38) | PTGDR2ALDH1A1LMNAAPPSNCA | |
| SCHEMBL2087962 | 0.89 | PTGDR2 (0.47) | PTGDR2ALDH1A1LMNAAPPSNCA | |
| SCHEMBL2087961 | 0.89 | PTGDR2 (0.47) | PTGDR2ALDH1A1LMNAAPPSNCA | |
| SCHEMBL2088336 | 0.88 | PTGDR2 (0.48) | PTGDR2ALDH1A1LMNAAPPSNCA | |
| SCHEMBL2088337 | 0.88 | PTGDR2 (0.48) | PTGDR2ALDH1A1LMNAAPPSNCA | |
| SCHEMBL2088024 | 0.86 | ALDH1A1 (0.49) | PTGDR2ALDH1A1LMNAAPPSNCA | |
| SCHEMBL2088022 | 0.86 | ALDH1A1 (0.49) | PTGDR2ALDH1A1LMNAAPPSNCA | |
| SCHEMBL2087657 | 0.85 | PTGDR2 (0.54) | PTGDR2ALDH1A1SLC16A1KDM4ETHRB | |
| SCHEMBL2087654 | 0.85 | PTGDR2 (0.54) | PTGDR2ALDH1A1SLC16A1KDM4ETHRB | |
| SCHEMBL2087639 | 0.82 | PTGDR2 (0.48) | PTGDR2ALDH1A1LMNAAPPSNCA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7897788-B2 | Indol-1-yl-acetic acid derivatives | ACTELION PHARMACEUTICAL LTD. (CH) | 2011-03-01 | — | — | US | disclosed |
| US-20070208004-A1 | Indol-1-yl-acetic acid derivatives | ACTELION PHARMACEUTICALS, LTD. (CH) | 2007-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070208004-A1 | Indol-1-yl-acetic acid derivatives | IDO1, IDO2, AANAT | PTGDR2 2853/4885ALDH1A1 67/4885LMNA 1896/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.